Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fairshter, R.
Right arrow Articles by Wilson, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fairshter, R.
Right arrow Articles by Wilson, A.

Chest, Vol 78, 44-50, Copyright © 1980 by American College of Chest Physicians


ARTICLES

Response to inhaled metaproterenol and isoproterenol in asthmatic and normal subjects

RD Fairshter and AF Wilson

Pulmonary function tests were performed before and after inhalation of 1.3 mg of metaproterenol sulfate or 150 microgram of isoproterenol hydrochloride by 40 asthmatic and 40 normal subjects. PHysiologic measurements included spirometric testing, plethysmographic studies, and maximal expiratory flow-volume curves obtained after inhalation of air and a mixture of 80 percent helium and 20 percent oxygen. In the normal subjects, pulmonary function improved significantly after inhalation of both metaproterenol and isoproterenol. There was no significant difference in responsiveness to either bronchodilator drug. In the asthmatic subjects, pulmonary function also improved significantly after both bronchodilator agents. The sites of predominant bronchodilatation were similar in the asthmatic subjects after both metaproterenol and isoproterenol; however, bronchodilatation was better overall (P less than 0.005) and for most individual tests with metaproterenol. The greater efficacy of metaproterenol in asthmatic subjects but not in normal subjects can be explained by (1) different doses of the bronchodilator drug and (2) differing bronchodilator dose-response relationships in asthmatic and normal subjects.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by the American College of Chest Physicians.